4D Molecular Therapeutics Stock

4D Molecular Therapeutics’ mission is to design and develop transformative gene therapy products using our proprietary.

About 4D Molecular Therapeutics Stock

4D Molecular Therapeutics, we are unlocking the full potential of the gene therapy field. Our customized AAV vectors can deliver genes to any cell in the body to eradicate disease.

Funding History

August 2015	$7.0M
September 2017	$3.0M

Management

Co-Founder

David Schaffer

COO

Anthony Davies

Co-Founder, President & CEO

David Kirn

Press

Roche boosts its gene therapy game, expanding partnership with 4D Molecular Therapeutics

Endpoints News - May, 1 2018

4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy ...

Business Wire (press release) - Apr, 30 2018

4D Molecular Therapeutics Receives $3 Million Follow-On Funding from Cystic Fibrosis Foundation Therapeutics for ...

Business Wire (press release) - Sep, 19 2017

Other Companies

Learn More

Biolife4D

BIOLIFE4D is committed to perfecting the technology to make viable organ replacement a safe, accessible and affordable reality.

Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.

Contract research organization and genome-scale diagnostics services company

Trigemina develops non-opiate drug formulations and delivery systems for pain therapy.

14Age (years)

$23.1MTotal Funding

EquityZen does not have an affiliation with, formal relationship with, or endorsement from 4D Molecular Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Trending Companies

Join 150K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Why EquityZen?

EquityZen helps investors to access private companies and their employees to sell shares.

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.

EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.
EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
© 2020 EquityZen Inc. All rights reserved.